An analysis of the use of dogs in predicting human toxicology and drug safety

Alternatives to Laboratory Animals

Volumn 41, Issue 5, 2013, Pages 335-350

  Bailey, Jarrod ^a   Thew, Michelle ^a   Balls, Michael ^b  

^a British Union for the Abolition of Vivisection (BUAV)   (United Kingdom)

^b RUSSELL AND BURCH HOUSE   (United Kingdom)

Author keywords

Canine; Dog; Drug development; Preclinical testing; Toxicology

Indexed keywords

ARTICLE; DRUG INDUSTRY; DRUG SAFETY; DRUG TISSUE LEVEL; EXPERIMENTAL DOG; HEART VENTRICLE CONDUCTION; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; NONHUMAN; PREDICTION; PRIORITY JOURNAL; TOXICITY; TOXICITY TESTING; VASCULAR DISEASE;

ANIMAL EXPERIMENTATION; ANIMAL USE ALTERNATIVES; ANIMALS; DOGS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LIKELIHOOD FUNCTIONS;

EID: 84892847151     PISSN: 02611929     EISSN: None     Source Type: Journal    
DOI: 10.1177/026119291304100504     Document Type: Article

References (54)

1. Anon. (2004). Directive 2004/27/EEC of the European Parliament and the Council of 31 March 2004, amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union L136, 30.04.2004, 34-57.
2. Anon. (2010). Federal Food, Drug and Cosmetics Act. Silver Spring, MD, USA: US Food and Drug Administration. Available at: http://www.fda.gov/ RegulatoryInformation/Legislation/FederalFood DrugandCosmeticActFDCAct/default. htm (Accessed 11.10.13).
3. Duyk, G. (2003). Attrition and translation. Science, New York 302, 603-605.
4. Kola, I. & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery 3, 711-715.
5. Aithal, G.P. (2010). Mind the gap. ATLA 38, Suppl. 1, 1-4.
6. UK Home Office (2013). Statistics of Scientific Procedures on Living Animals - Great Britain 2012. HC 549, 60pp. London, UK: The Stationery Office.
7. USDA (2011). Annual Report. Animal Usage by Fiscal Year - Fiscal Year 2010, 2pp. Riverdale, MD, USA: United States Department of Agriculture (USDA), Animal and Plant Health Inspection Service (APHIS). Available at: http://www.aphis. usda.gov/animal-welfare/efoia/downloads/2010-Animals-Used-In- Research.pdf (Accessed 05.09. 13).
8. Anon. (2010). Sixth Report on the Statistics on the Number of Animals Used for Experimental and Other Scientific Purposes in the Member States of the European Union. SEC(2010) 1107, 14pp. Brussels, Belgium: European Commission. Available at: http://eurlex.europa.eu/LexUriServ/LexUriServ.do? uri=COM:2010:0511:REV1:EN:PDF (Accessed 10. 10.13).
9. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., Dorato, M., Van Deun, K., Smith, P., Berger, B. & Heller, A. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology & Pharmacology 32, 56-67.
10. Altman, D.G. & Bland, J.M. (1994). Diagnostic tests 2: Predictive values. British Medical Journal 309, 102.
11. Anon. (2012). Likelihood Ratios. Oxford, UK: Centre for Evidence Based Medicine (CEBM). Available at: http://www.cebm.net/index.aspx?o= 1043 (Accessed 10.10.13).
12. Greek, R. & Menache, A. (2013). Systematic reviews of animal models: Methodology versus epistemology. International Journal of Medical Sciences 10, 206-221.
13. Grimes, D.A. & Schulz, K.F. (2005). Refining clinical diagnosis with likelihood ratios. Lancet 365, 1500-1505.
14. Hasiwa, N., Bailey, J., Clausing, P., Daneshian, M., Eileraas, M., Farkas, S., Gyertyan, I., Hubrecht, R., Kobel, W., Krummenacher, G., Leist, M., Lohi, H., Miklosi, A., Ohl, F., Olejniczak, K., Schmitt, G., Sinnett-Smith, P., Smith, D., Wagner, K., Yager, J.D., Zurlo, J. & Hartung, T. (2011). Critical evaluation of the use of dogs in biomedical research and testing in Europe. ALTEX 28, 326-340.
15. van Meer, P.J., Kooijman, M., Gispen-de Wied, C.C., Moors, E.H. & Schellekens, H. (2012). The ability of animal studies to detect serious post marketing adverse events is limited. Regulatory Toxicology & Pharmacology 64, 345-349.
16. Igarashi, T., Nakane, S. & Kitagawa, T. (1995). Predictability of clinical adverse reactions of drugs by general pharmacology studies. Journal of Toxicological Sciences 20, 77-92.
17. Broadhead, C.L., Jennings, M. & Combes, R. (1999). A Critical Evaluation of the Use of Dogs in the Regulatory Toxicity Testing of Pharmaceuticals, 106pp. Nottingham, UK: Fund for the Replacement of Animals in Medical Experiments (FRAME).
18. Litchfield, J.T.J. (1962). Symposium on clinical drug evaluation and human pharmacology. XVI. Evaluation of the safety of new drugs by means of tests in animals. Clinical Pharmacology & Thera-peutics 3, 665-672.
19. Bailey, J. (2008). Developmental toxicity testing: Protecting future generations? ATLA 36, 718-721.
20. Schardein, J. (2000). Chemically Induced Birth Defects, 3rd edn, 1019pp. Boca Raton, FL, USA: CRC Press.
21. Spanhaak, S., Cook, D., Barnes, J. & Reynolds, J. (2008). Species Concordance for Liver Injury, 6pp. Cambridge, UK: Biowisdom Ltd. Available at: http://www.biowisdom.com/files/SIP-Board-Species -Concordance.pdf (Accessed 10.10.13).
22. Matthews, R.A. (2008). Medical progress depends on animal models - doesn't it? Journal of the Royal Society of Medicine 101, 95-98.
23. Barnes, J.C., Matis, S., Kenna, G., Swinton, J., Bradley, P.M., Day, N.C., Reed, J.Z., Reynolds, J. & Cook, D. (2008). The Safety Intelligence Program: An Intelligence Network for Drug-induced Liver Injury, 2pp. Cambridge, UK: Biowisdom Ltd. Available at: http://bioblog.instem.com/downloads/Carboxylic- acids-A4.pdf (Accessed 10.10.13).
24. Sidaway, J.R.M., Roberts, S., Huby, R., Nicholson, A., Pemberton, J., South, M., Noeske, T., Engkvist, O., Bradley, P. & Reed, J. (2012). Drug Toxicities Associated With Pharmacological Activity: Using Harmonised Data to Make the 'Known' Visible, 2pp. Macclesfield, UK: Safety Assessment, AstraZeneca. Available at: http://bioblog.instem.com/wp-content/uploads/downloads/2012/03/ SOT2012-make-theknown-visible-poster.pdf (Accessed 10.10.13).
25. Fourches, D., Barnes, J.C., Day, N.C., Bradley, P., Reed, J.Z. & Tropsha, A. (2010). Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical Research in Toxicology 23, 171-183.
26. Greco, I., Day, N., Riddoch-Contreras, J., Reed, J., Soininen, H., Kloszewska, I., Tsolaki, M., Vellas, B., Spenger, C., Mecocci, P., Wahlund, L.O., Simmons, A., Barnes, J. & Lovestone, S. (2012). Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation. Journal of Translational Medicine 10, 217.
27. Wandall, B., Hansson, S.O. & Ruden, C. (2007). Bias in toxicology. Archives of Toxicology 81, 605-617.
28. Hackam, D.G. (2007). Translating animal research into clinical benefit. British Medical Journal 334, 163-164.
29. ter Riet, G., Korevaar, D.A., Leenaars, M., Sterk, P.J., Van Noorden, C.J., Bouter, L.M., Lutter, R., Elferink, R.P. & Hooft, L. (2012). Publication bias in laboratory animal research: A survey on magnitude, drivers, consequences and potential solutions. PLoS One 7, e43404.
30. Briel, M., Muller, K.F., Meerpohl, J.J., von Elm, E., Lang, B., Motschall, E., Gloy, V., Lamontagne, F., Schwarzer, G. & Bassler, D. (2013). Publication bias in animal research: A systematic review protocol. Systematic Reviews 2, 23.
31. van der Worp, H.B., Howells, D.W., Sena, E.S., Porritt, M.J., Rewell, S., O'Collins, V. & Macleod, M.R. (2010). Can animal models of disease reliably inform human studies? PLoS Medicine 7, e1000245.
32. Sena, E.S., van der Worp, H.B., Bath, P.M., Howells, D.W. & Macleod, M.R. (2010). Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biology 8, e1000344.
33. Perel, P., Roberts, I., Sena, E., Wheble, P., Briscoe, C., Sandercock, P., Macleod, M., Mignini, L.E., Jayaram, P. & Khan, K.S. (2007). Comparison of treatment effects between animal experiments and clinical trials: Systematic review. British Medical Journal 334, 197.
34. Schott, G., Pachl, H., Limbach, U., Gundert-Remy, U., Ludwig, W.D. & Lieb, K. (2010). The financing of drug trials by pharmaceutical companies and its consequences. Part 1: A qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Deutsches Arzteblatt International 107, 279-285.
35. Kilkenny, C., Parsons, N., Kadyszewski, E., Festing, M.F., Cuthill, I.C., Fry, D., Hutton, J. & Altman, D.G. (2009). Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One 4, e7824.
36. Anon. (2010). Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Official Journal of the European Union L276, 20.10.2010, 33-79.
37. US FDA (2004). Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products, 12pp. Silver Spring, MD, USA: US Department of Health and Human Services, Food and Drug Administration. Available at: http://www.fda.gov/ScienceResearch/Special Topics/CriticalPath Initiative/CriticalPathOpportunitiesReports/ucm077 262.htm (Accessed 10.10.13).
38. Issa, A.M., Phillips, K.A., Van Bebber, S., Nidamarthy, H.G., Lasser, K.E., Haas, J.S., Alldredge, B.K., Wachter, R.M. & Bates, D.W. (2007). Drug withdrawals in the United States: A systematic review of the evidence and analysis of trends. Current Drug Safety 2, 177-185.
39. Bennani, Y.L. (2011). Drug discovery in the next decade: Innovation needed ASAP. Drug Discovery Today 16, 779-792.
40. Eichler, H.G., Aronsson, B., Abadie, E. & Salmonson, T. (2010). New drug approval success rate in Europe in 2009. Nature Reviews Drug Discovery 9, 355-356.
41. Hughes, B. (2008). 2007 FDA drug approvals: A year of flux. Nature Reviews Drug Discovery 7, 107-109.
42. Hartung, T. (2009). Toxicology for the twenty-first century. Nature, London 460, 208-212.
43. Harding, A. (2004). More compounds failing phase I. FDA chief warns that high drug attrition rate is pushing up the cost of drug development. The Scientist, 6 August 2004. Available at: http://www.the-scientist.com/?articles. view/articleNo/23003/title/More-compounds-failing-Phase-I/ (Accessed 10.10.13).
44. Okie, S. (2006). Access before approval - a right to take experimental drugs? New England Journal of Medicine 355, 437-440.
45. Aurup, P. (2012). Er Danmark et Attraktivt Land for Klinisk Forskning? (Is Denmark an Attractive Country for Clinical research?), 23pp. Ballerup, Denmark: MSD Laboratories. Available at: http://di.dk/SiteCollectionDocuments/ Opinion/Sundhed/Høring/Præsentation%20-%20Peter%20Aurup, %20Merck.pdf (Accessed 10.10.13).
46. Anon. (1990). FDA Drug Review: Post Approval Risks 1976-1985. GAO/PEMD-90-15, 132pp. Washington, DC, USA: US General Accounting Office. Available at: http://161.203.16.4/d24t8/141456.pdf (Accessed 10.10.13).
47. Lazarou, J., Pomeranz, B.H. & Corey, P.N. (1998). Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. Journal of the American Medical Association 279, 1200-1205.
48. Gad, S.C. (2006). Animal Models in Toxicology, 952pp. Boca Raton, FL, USA: CRC Press.
49. Martinez, M.N., Antonovic, L., Court, M., Dacasto, M., Fink-Gremmels, J., Kukanich, B., Locuson, C., Mealey, K., Myers, M.J. & Trepanier, L. (2013). Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics. Drug Metabolism Reviews 45, 218-230.
50. Broadhead, C.L., Betton, G., Combes, R., Damment, S., Everett, D., Garner, C., Godsafe, Z., Healing, G., Heywood, R., Jennings, M., Lumley, C., Oliver, G., Smith, D., Straughan, D., Topham, J., Wallis, R., Wilson, S. & Buckley, P. (2000). Prospects for reducing and refining the use of dogs in the regulatory toxicity testing of pharmaceuticals. Human & Experimental Toxicology 19, 440-447.
51. Spielmann, H., Kral, V., Schäfer-Korting, M., Seidle, T., McIvor, E., Rowan, A. & Schoeters, G. (2011). The AXLR8 Consortium. Alternative Testing Strategies, Progress Report 2011, 364pp. Berlin, Germany: Institute of Pharmacy, Free University of Berlin. Available at: http://scrtox.eu/~scrtox/ images/stories/AXLR8-2011.pdf (Accessed 10.10.13).
52. Anon. (2007). Toxicity Testing for the 21st Century: A Vision and a Strategy, 216pp. Washington, DC, USA: National Academies Press.
53. Anon. (2009). Public Opinion. London, UK: European Coalition to End Animal Experiments. Available at: http://www.eceae.org/en/what-we-do/campaigns/ 12-million-reasons/public-opinion (Accessed 10.10.13).
54. Hare, B., Brown, M., Williamson, C. & Tomasello, M. (2002). The domestication of social cognition in dogs. Science, New York 298, 1634-1636.